A prior study by Packer et al.31 revealed that PI3K inhibitors enhanced the anti-tumor efficacies of anti-FGFR inhibitors in vitro in endometrial cancers in which the activation of the PI3K pathway was observed in > 90% of FGFR2-mutated cases. Here, FGFR2 is linked to endometrial cancer.